References
- Aleem, A., Akbar Samad, A. B., Slenker, A. K. (2022). Emerging variants of SARS-CoV-2 and novel therapeutics gainst coronavirus (COVID-19). In: StatPearls. StatPearls Publishing.
- Almehdi, A. M., Khoder, G., Alchakee, A. S., Alsayyid, A. T., Sarg, N. H., Soliman, S. (2021). SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies. Infection, 49 (5), 855–876. https://doi.org/10.1007/s15010-021-01677-8.
- Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S. et al. (2020). Remdesivir for the treatment of covid-19 — final report. New Engl. J. Med., 383 (19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764.
- Bhaskaran, K., Bacon, S., Evans, S. J., Bates, C. J., Rentsch, C. T., MacKenna, B., Tomlinson, L., Walker, A. J., Schultze, A., Morton, C. E. et al. (2021). Factors associated with deaths due to COVID-19 versus other causes: Population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet Regional Health. Europe, 6, 100109. https://doi.org/10.1016/j.lanepe.2021.100109.
- Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., Cordero, A. (2020). The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. J. Amer. Med. Dir. Assoc., 21 (7), 915–918. https://doi.org/10.1016/j.jamda.2020.05.045.
- Butt, A. A., Dargham, S. R., Chemaitelly, H., Al Khal, A., Tang, P., Hasan, M. R., Coyle, P. V., Thomas, A. G., Borham, A. M., Concepcion, E. G. et al. (2022). Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in qatar. JAMA Int. Med., 182 (2), 197–205. https://doi.org/10.1001/jamainternmed.2021.7949.
- Centers for Disease Control and Prevention (2022). What is the difference between Influenza (Flu) and COVID-19? https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm (accessed 10.06.2022).
- Du, Y., Zhou, N., Zha, W., Lv, Y. (2021). Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. Nutrit. Metab. Cardiovasc. Dis., 31 (3), 745–755. https://doi.org/10.1016/j.numecd.2020.12.009.
- Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeili, S. M., Bahreini, E. (2020). A comprehensive review of COVID-19 characteristics. Biol. Proced. Online, 22, 19. https://doi.org/10.1186/s12575-020-00128-2.
- Geldsetzer, P., Mukama, T., Jawad, N. K., Riffe, T., Rogers, A., Sudharsanan, N. (2022). Sex differences in the mortality rate for coronavirus disease 2019 compared to other causes of death: An analysis of population-wide data from 63 countries. Eur. J. Epidemiol., 37 (8), 797–806. https://doi.org/10.1007/s10654-022-00866-5.
- Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M. et al. (2022). Early remdesivir to prevent progression to severe covid-19 in outpatients. New Engl. J. Med., 386 (4), 305–315. https://doi.org/10.1056/NEJMoa2116846.
- Hippisley-Cox, J., Young, D., Coupland, C., Channon, K. M., Tan, P. S., Harrison, D. A., Rowan, K., Aveyard, P., Pavord, I. D., Watkinson, P. J. (2020). Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart (British Cardiac Society), 106 (19), 1503–1511. https://doi.org/10.1136/heartjnl-2020-317393.
- Johansson, M. A., Quandelacy, T. M., Kada, S., Prasad, P. V., Steele, M., Brooks, J. T., Slayton, R. B., Biggerstaff, M., Butler, J. C. (2021). SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Network Open, 4 (1), e2035057. https://doi.org/10.1001/jamanetworkopen.2020.35057.
- Kompaniyets, L., Pennington, A. F., Goodman, A. B., Rosenblum, H. G., Belay, B., Ko, J. Y., Chevinsky, J. R., Schieber, L. Z., Summers, A. D., Lavery, A. M., et al. (2021). Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prevent. Chronic Dis., 18, E66. https://doi.org/10.5888/pcd18.210123.
- Mohapatra, R. K., Pintilie, L., Kandi, V., Sarangi, A. K., Das, D., Sahu, R., Perekhoda, L. (2020). The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. Chem. Biol. Drug Design, 96 (5), 1187–1208. https://doi.org/10.1111/cbdd.13761.
- Ng, W. H., Tipih, T., Makoah, N. A., Vermeulen, J. G., Goedhals, D., Sempa, J. B., Burt, F. J., Taylor, A., Mahalingam, S. (2021). Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. mBio, 12 (1), e03647-20. https://doi.org/10.1128/mBio.03647-20.
- Péterfi, A., Mészáros, Á., Szarvas, Z., Pénzes, M., Fekete, M., Fehér, Á., Lehoczki, A., Csípõ, T., Fazekas-Pongor, V. (2022). Comorbidities and increased mortality of COVID-19 among the elderly: A systematic review. Physiol. Int., 10.1556/2060.2022.00206. https://doi.org/10.1556/2060.2022.00206
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C. et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl. J. Med., 383 (27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577.
- Rogers, K. (2022). COVID-19 vaccine. Encyclopedia Britannica. https://www.britannica.com/science/COVID-19-vaccine (accessed 15.06.2022).
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., Altaf, M. (2020). Comorbidity and its impact on patients with COVID-19. SN Comprehens. Clin. Med., 2 (8), 1069–1076. https://doi.org/10.1007/s42399-020-00363-4.
- Singh, A. K., Gupta, R., Ghosh, A., Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr., 14 (4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004.
- Tanni, S. E., Silvinato, A., Floriano, I., Bacha, H. A., Barbosa, A. N., Bernardo, W. M. (2022). Use of remdesivir in patients with COVID-19: A systematic review and meta-analysis. Jornal Brasileiro de Pneumologia, 48 (1), e20210393. https://doi.org/10.36416/1806-3756/e20210393.
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 30 (3), 269–271. https://doi.org/10.1038/s41422-020-0282-0.
- World Health Organisation (2020). Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (accessed 15.06.2022).
- World Health Organisation. WHO Coronavirus (COVID-19) Dashboard 2022. https://covid19.who.int/ (accessed 15.06.2022).
- Wrenn, J. O., Pakala, S. B., Vestal, G., Shilts, M. H., Brown, H. M., Bowen, S. M., Strickland, B. A., Williams, T., Mallal, S. A., Jones, I. D. et al. (2022). COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. Influenza Other Respir. Viruses, 16 (5), 832–836. 10.1111/irv.12982. https://doi.org/10.1111/irv.12982.
- Zoumpourlis, V., Goulielmaki, M., Rizos, E., Baliou, S., Spandidos, D. A. (2020). The COVID-19 pandemic as a scientific and social challenge in the 21st century. Mol. Med. Rep., 22 (4), 3035–3048. https://doi.org/10.3892/mmr.2020.11393.